Simplify Logo
Sanofi

Sanofi

Global pharma company; vaccines and R&D

Medical Director Influenza Vaccines

Full-TimePosted on 9/17/2026Deadline 12/31/26
$178.5k - $257.8k/yr
Senior
PharmD, PhD, MD, Doctor of Osteopathic Medicine (DO)
Morristown, NJ, USA
Hybrid

Up to 20% travel required.

About the job

Requirements
  • An advanced degree (PhD, PharmD, DO, or MD) in a scientific or healthcare-related discipline such as vaccinology, immunology, microbiology, infectious disease, or a related field.
  • At least 5 years of experience in Medical Affairs within the pharmaceutical or biotechnology industry or a related field such as public health or academia.
  • Relevant clinical experience or a track record of peer-reviewed publications in the United States.
  • Ability to travel up to 20% of the time.
  • Knowledge of the U.S. healthcare system, communicable disease control, public health, and immunization practices.
  • Knowledge of vaccine study design and interpretation for interventional and observational studies.
  • Ability to understand and effectively communicate vaccine clinical studies, including interventional and observational studies.
  • Ability to manage multiple projects simultaneously, plan and prioritize work, and implement actions using a self-dependent and structured working style.
  • Ability to work as part of a cross-functional and multicultural team.
Responsibilities
  • Contribute to the development and execution of the non-promotional medical and scientific strategy for the U.S. influenza vaccine franchise portfolio.
  • Own the medical plan, data generation, scientific exchange, and stakeholder engagement for the defined franchise and scope.
  • Partner cross-functionally with the U.S. Medical team, brand teams, Public Affairs, and other departments.
  • Develop, execute, and contribute to the Country Medical Roadmap and annual cross-functional brand planning process.
  • Align U.S. medical strategy with the global medical strategy through collaboration with the global medical team.
  • Shape medical strategy at global, regional, and local levels while monitoring publications and determining appropriate dissemination to external stakeholders.
  • Serve as the country medical expert for the Integrated Evidence Generation Plan and liaise between global Medical, the Principal Investigator, and the U.S. Medical Team on Sanofi-sponsored studies.
  • Establish and maintain strategic relationships with senior experts, key opinion leaders, professional societies, immunization advisory bodies, patient advocacy groups, decision makers, and other external stakeholders.
  • Provide external scientific education on disease states, epidemiology, and clinical trials, and provide guidance on company products and related medical issues.
  • Evaluate medical educational grant requests in accordance with internal procedures and the Country Medical Plan.
  • Lead external advisory boards supporting medical strategic objectives and the medical plan.
  • Provide scientific expertise within and outside the franchise team.
  • Work with internal stakeholders, particularly field medical, to develop strategic imperatives and downstream strategies and tactics.
  • Train the field-based medical team on current and new publications and related assets.
  • Provide medical guidance to internal Sanofi customers, including medical information and clinical trial data for pharmacovigilance and regulatory reports to the U.S. Food and Drug Administration and other health authorities.
  • Collaborate with marketing teams to connect evidence with brand strategy.
  • Represent the country medical function in product label updates and Company Core Datasheet updates.
  • Provide medical input into the design and execution of company-sponsored Phase 4 post-marketing and observational studies.
  • Write, review, edit, and approve key regulatory documents with Research and Development and Clinical Development teams.
  • Engage key external leaders to support investigator-sponsored studies aligned with Life Cycle Management and Global Brand Team strategies.
  • Oversee the investigator-initiated study process from application through completion and publication.
  • Review investigator-sponsored study and external scientific committee applications.
  • Liaise with investigators regarding study applications.
  • Present studies to the Global Medical Team and Scientific Review Committee.
  • Follow study progress through completion and eventual publication.
  • Participate as a subject matter expert in multidisciplinary Review Committee meetings for medical review and approval of external materials and messaging.
  • Contribute to the development and management of owned franchise budget line items by tracking expenditures and executing plans cost-effectively.
  • Monitor publications outlined in the Country Medical Plan and determine appropriate assets for targeted external stakeholders.
Desired Qualifications
  • Prior experience in an external stakeholder-facing role, including governmental collaboration.
  • Recognition by vaccine experts as an expert in vaccinology or a related discipline.
  • Infectious disease and/or vaccine experience from academia, research, or the pharmaceutical industry with relevant customer knowledge.
  • Developed business acumen to support effective Medical strategies for patients, healthcare professionals, and external stakeholders.
  • Experience with medical strategy, vaccine clinical studies, and scientific stakeholder engagement.
  • Excellent interpersonal, communication, influencing, and networking skills.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.